nach oben

International Journal of Hematology

Erschienen in:

01.11.2018 | Images in Hematology

Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia

verfasst von: Tatsuya Konishi, Noriko Doki, Yasunobu Takaki, Aiko Igarashi, Kazuteru Ohashi

Erschienen in: International Journal of Hematology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Accumulated clinical experience has now provided clear and convincing evidence that erythropoietin-stimulating agents (ESAs), alone or in combination with granulocyte-stimulating factor, are efficacious in patients with low-risk myelodysplastic syndrome (MDS). Moreover, the relative safety of prolonged use of ESA has resulted in widespread use in patients with MDS. We here report a unique case of presacral mass due to extramedullary hematopoiesis (EMH), which was first observed before treatment with ESAs, but which more than doubled in a diameter after 3 years ESA treatment for myelodysplasia. …

Buccisano F, Maurillo L, Neri B, Masala S, Mauriello A, Del Principe MI, et al. Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes. J Clin Oncol. 2013 31(11):e189–91.CrossRef

Titel: Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia
verfasst von: Tatsuya Konishi
Noriko Doki
Yasunobu Takaki
Aiko Igarashi
Kazuteru Ohashi
Publikationsdatum: 01.11.2018
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 1/2019
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-018-2554-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study

Massive bone marrow necrosis revealing an HIV-related primary bone marrow lymphoma: a diagnostic challenge

Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy

Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation

Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults

Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie